Table 2.

Studies reporting PAI-1 activity levels (IU/mL) and major adverse cardiovascular events and restenosis

					Event						No Event
Reference	Year	Study Design	Follow-up (months)	Population of interest	N	PAI-1 Activity (U/mL)	Range	Death	MI	Restenosis	N	PAI-1 Activity (U/mL)	Range
Sane et al. [50]	1991	Cohort	24	Fibrinolytics	28	17	16	n/a	n/a	28	328	19	21
Shah et al. [72]	1992	Cohort	9	Elective PCI	28	8	7.1	n/a	n/a	28	40	12	8
Gray et al. [73]	1993	Cohort	0.1	MI	13	20.6	11	n/a	13	n/a	85	20.1	7.9
Malmberg et al. [74]	1994	Case-Control	90	MI	53	23.75	13.34	20	33	n/a	55	18	10.97
Brack et al. [75]	1994	Cohort	4	Elective PCI	16	4.63	4.71	n/a	n/a	16	30	5.77	5.06
Nordt et al. [54]	1998	Cohort	12	Fibrinolytics	5	8.7	8.3	n/a	5	n/a	26	9.9	8.2
Jansson et al. [76]	1998	Cohort	120	MI	54	9.1	5.1	54	n/a	n/a	69	10.6	7.1
Wiman et al. [77]	2000	Case-Control	3	MI	61	22.1	17.5	n/a	61	n/a	95	18.2	16.5
Wiman et al. [77]	2000	Case-Control	3	Ml	25	15.4	13.6	n/a	25	n/a	38	17.8	12.4
Prisco et al. [78]	2001	Cohort	18	MI	18	11.27	7.64	n/a	n/a	18	36	15.8	27.49
Prisco et al. [78]	2001	Cohort	18	Elective PCI	6	8.33	8.1	n/a	n/a	6	42	7.57	9.52
Sargento et al. [79]	2003	Cohort	12	MI	7	6.34	1.56	5	2	n/a	80	4.47	1.84
Marcucci et al. [19]	2006	Case-Control	22 2	MI	109	22	9.09	54	55	n/a	411	24.25	10.63
Schoebel et al. [80]	2008	Cohort	2	MI	18	3.7	1.8	n/a	n/a	18	42	5.3	3.2

Wiman et al. [77] is presented twice as data for men and women were reported separately